Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy

Blood Cells, Molecules, and Diseases

Volumn 52, Issue 2-3, 2014, Pages 121-125

  Ferri, Cristian ^a   Bianchini, Michele ^a   Bengió, Raquel ^b   Larripa, Irene ^a,b  

^a Instituto de Medicina Experimental   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Chronic myeloid leukemia; LYN; PTEN; Resistance; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL METABOLISM; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; LYN GENE; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PTEN GENE; STEM CELL; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ACCELERATED PHASE/BLAST PHASE TREATED WITH DASATINIB; ACCELERATED PHASE/BLAST PHASE TREATED WITH IMATINIB OR NILOTINIB; AP/BP-D; AP/BP-IN; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE TREATED WITH DASATINIB; CHRONIC PHASE TREATED WITH IMATINIB OR NILOTINIB; CML; CP-D; CP-IN; CT; HD; HEALTHY DONORS; KD; KINASE DOMAIN; LYN; OPTIMAL RESPONDERS; OPTIMAL RESPONDERS TO TKI TREATED WITH DASATINIB; OPTIMAL RESPONDERS TO TKI TREATED WITH IMATINIB OR NILOTINIB; OR; OR-D; OR-IN; PTEN; RESISTANCE; THRESHOLD CYCLE; TKI; TYROSINE KINASE INHIBITOR; TYROSINE KINASE INHIBITORS;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; SRC-FAMILY KINASES;

EID: 84891901388     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.09.002     Document Type: Article

References (31)

1. Lugo T., Pendergast A., Muller A., Witte O. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
2. Druker B., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
3. Branford S., Melo J., Hughes T. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matterα. Blood 2009, 114:5426-5435.
4. Khorashad J., Anand M., Marin D., et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20:658-663.
5. Ernst T., La Rosée P., Müller M., Hochhaus A. BCR-ABL mutations in chronic myeloid leukemia. Hematol. Oncol. Clin. North Am. 2011, 25:997-1008.
6. Branford S., Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol. Med. 2006, 125:93-106.
7. Bixby D., Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011, 25:7-22.
8. Faderl S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999, 341:164-172.
9. Sattler M., Griffin J. Mechanisms of transformation by the BCR/ABL oncogene. Int. J. Hematol. 2001, 73:278-291.
10. Nieborowska-Skorska M., Wasik M., Slupianek A., et al. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 andSH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 1999, 189:1229-1242.
11. Roginskaya V., Zuo S., Caudell E., et al. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999, 13:855-861.
12. Danhauser-Riedl S., Warmuth M., Druker B., et al. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996, 56:3589-3596.
13. Saglio G., Kim D., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259.
14. Wei G., Rafiyath S., Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J. Hematol. Oncol. 2010, 3:47.
15. Hu Y., Liu Y., Pelletier S., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 2004, 36:453-461.
16. Lionberger J., Wilson M., Smithgall T. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. 2000, 275:18581-18585.
17. Wilson M., Schreiner S., Choi H., et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002, 21:8075-8088.
18. Meyn M., Wilson M., Abdi F., et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J. Biol. Chem. 2006, 281:30907-30916.
19. Warmuth M., Bergmann M., Priess A., et al. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. 1997, 272:33260-33270.
20. Peng C., Chen Y., Yang Z., et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood Jan 21 2010, 115:626-635.
21. Carpten J., Faber A., Horn C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
22. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
23. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273:13375-13378.
24. Stambolic V., Suzuki A., de la Pompa J., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
25. Rameh L., Cantley L. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 1999, 274:8347-8350.
26. Va'rnai P., Bondeva T., Tamas P., et al. Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners. J. Cell Sci. 2005, 118:4879-4888.
27. Ferri C., Bianchini M., Icardi G., et al. Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction. Leuk. Lymphoma 2013, 54:598-606.
28. Hughes T.P., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
29. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
30. Wu J., Meng F., Kong L., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl. Cancer Inst. 2008, 100:926-939.
31. Peng C., Chen Y., Li D., Li S. Role of Pten in leukemia stem cells. Oncotarget 2010, 1:156-160.